nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—TNF—liver cancer	0.62	1	CbGaD
Pomalidomide—CYP1A2—Sorafenib—liver cancer	0.0256	0.308	CbGbCtD
Pomalidomide—ABCB1—Sorafenib—liver cancer	0.0224	0.269	CbGbCtD
Pomalidomide—ABCB1—Doxorubicin—liver cancer	0.0136	0.163	CbGbCtD
Pomalidomide—CYP3A4—Sorafenib—liver cancer	0.0134	0.161	CbGbCtD
Pomalidomide—CYP3A4—Doxorubicin—liver cancer	0.00813	0.0979	CbGbCtD
Pomalidomide—Peripheral sensory neuropathy—Sorafenib—liver cancer	0.00586	0.0386	CcSEcCtD
Pomalidomide—Pneumocystis jirovecii pneumonia—Epirubicin—liver cancer	0.00493	0.0325	CcSEcCtD
Pomalidomide—Pneumocystis jirovecii pneumonia—Doxorubicin—liver cancer	0.00456	0.0301	CcSEcCtD
Pomalidomide—Neutropenic sepsis—Epirubicin—liver cancer	0.00357	0.0235	CcSEcCtD
Pomalidomide—Embolism venous—Sorafenib—liver cancer	0.00332	0.0219	CcSEcCtD
Pomalidomide—Neutropenic sepsis—Doxorubicin—liver cancer	0.0033	0.0218	CcSEcCtD
Pomalidomide—Lymphopenia—Sorafenib—liver cancer	0.00327	0.0216	CcSEcCtD
Pomalidomide—Embolism—Sorafenib—liver cancer	0.00261	0.0172	CcSEcCtD
Pomalidomide—Interstitial lung disease—Sorafenib—liver cancer	0.00236	0.0156	CcSEcCtD
Pomalidomide—Tumour lysis syndrome—Epirubicin—liver cancer	0.00223	0.0147	CcSEcCtD
Pomalidomide—Peripheral sensory neuropathy—Epirubicin—liver cancer	0.00216	0.0143	CcSEcCtD
Pomalidomide—Venous thromboembolism—Epirubicin—liver cancer	0.0021	0.0139	CcSEcCtD
Pomalidomide—Tumour lysis syndrome—Doxorubicin—liver cancer	0.00206	0.0136	CcSEcCtD
Pomalidomide—Peripheral sensory neuropathy—Doxorubicin—liver cancer	0.002	0.0132	CcSEcCtD
Pomalidomide—Thalidomide—TNF—liver cancer	0.00199	0.395	CrCbGaD
Pomalidomide—Venous thromboembolism—Doxorubicin—liver cancer	0.00195	0.0128	CcSEcCtD
Pomalidomide—Hypocalcaemia—Sorafenib—liver cancer	0.00183	0.0121	CcSEcCtD
Pomalidomide—Musculoskeletal chest pain—Epirubicin—liver cancer	0.0016	0.0105	CcSEcCtD
Pomalidomide—Neuropathy—Sorafenib—liver cancer	0.00157	0.0104	CcSEcCtD
Pomalidomide—Thalidomide—CYP2E1—liver cancer	0.00153	0.304	CrCbGaD
Pomalidomide—Thalidomide—CYP1A1—liver cancer	0.00151	0.3	CrCbGaD
Pomalidomide—Musculoskeletal chest pain—Doxorubicin—liver cancer	0.00148	0.00974	CcSEcCtD
Pomalidomide—Cardiac failure congestive—Sorafenib—liver cancer	0.00134	0.00884	CcSEcCtD
Pomalidomide—Embolism venous—Epirubicin—liver cancer	0.00123	0.00809	CcSEcCtD
Pomalidomide—Hyponatraemia—Sorafenib—liver cancer	0.00122	0.00805	CcSEcCtD
Pomalidomide—Pain in extremity—Sorafenib—liver cancer	0.00121	0.00802	CcSEcCtD
Pomalidomide—Lymphopenia—Epirubicin—liver cancer	0.00121	0.00797	CcSEcCtD
Pomalidomide—Embolism venous—Doxorubicin—liver cancer	0.00113	0.00748	CcSEcCtD
Pomalidomide—Dehydration—Sorafenib—liver cancer	0.00113	0.00745	CcSEcCtD
Pomalidomide—Lymphopenia—Doxorubicin—liver cancer	0.00112	0.00738	CcSEcCtD
Pomalidomide—Dry skin—Sorafenib—liver cancer	0.00111	0.00735	CcSEcCtD
Pomalidomide—Hypokalaemia—Sorafenib—liver cancer	0.00111	0.0073	CcSEcCtD
Pomalidomide—Breast disorder—Sorafenib—liver cancer	0.0011	0.00724	CcSEcCtD
Pomalidomide—Nasopharyngitis—Sorafenib—liver cancer	0.00109	0.00717	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Sorafenib—liver cancer	0.00107	0.00707	CcSEcCtD
Pomalidomide—Febrile neutropenia—Epirubicin—liver cancer	0.00103	0.00678	CcSEcCtD
Pomalidomide—Pelvic pain—Epirubicin—liver cancer	0.00102	0.00671	CcSEcCtD
Pomalidomide—Neutropenia—Sorafenib—liver cancer	0.000982	0.00648	CcSEcCtD
Pomalidomide—Embolism—Epirubicin—liver cancer	0.000964	0.00636	CcSEcCtD
Pomalidomide—Febrile neutropenia—Doxorubicin—liver cancer	0.000951	0.00628	CcSEcCtD
Pomalidomide—Weight decreased—Sorafenib—liver cancer	0.00095	0.00627	CcSEcCtD
Pomalidomide—Pneumonia—Sorafenib—liver cancer	0.000942	0.00621	CcSEcCtD
Pomalidomide—Pelvic pain—Doxorubicin—liver cancer	0.000941	0.00621	CcSEcCtD
Pomalidomide—Infestation NOS—Sorafenib—liver cancer	0.000936	0.00618	CcSEcCtD
Pomalidomide—Infestation—Sorafenib—liver cancer	0.000936	0.00618	CcSEcCtD
Pomalidomide—Renal failure—Sorafenib—liver cancer	0.00092	0.00607	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Sorafenib—liver cancer	0.000918	0.00606	CcSEcCtD
Pomalidomide—Embolism—Doxorubicin—liver cancer	0.000892	0.00588	CcSEcCtD
Pomalidomide—Hypercalcaemia—Epirubicin—liver cancer	0.00089	0.00587	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Sorafenib—liver cancer	0.000885	0.00584	CcSEcCtD
Pomalidomide—Epistaxis—Sorafenib—liver cancer	0.000883	0.00583	CcSEcCtD
Pomalidomide—Urinary tract disorder—Sorafenib—liver cancer	0.00083	0.00548	CcSEcCtD
Pomalidomide—Connective tissue disorder—Sorafenib—liver cancer	0.000826	0.00545	CcSEcCtD
Pomalidomide—Urethral disorder—Sorafenib—liver cancer	0.000824	0.00544	CcSEcCtD
Pomalidomide—Hypercalcaemia—Doxorubicin—liver cancer	0.000824	0.00544	CcSEcCtD
Pomalidomide—Cardiac disorder—Sorafenib—liver cancer	0.00078	0.00515	CcSEcCtD
Pomalidomide—Angiopathy—Sorafenib—liver cancer	0.000763	0.00503	CcSEcCtD
Pomalidomide—Mediastinal disorder—Sorafenib—liver cancer	0.000757	0.005	CcSEcCtD
Pomalidomide—Mental disorder—Sorafenib—liver cancer	0.000736	0.00486	CcSEcCtD
Pomalidomide—Malnutrition—Sorafenib—liver cancer	0.000732	0.00483	CcSEcCtD
Pomalidomide—Muscle spasms—Sorafenib—liver cancer	0.000703	0.00464	CcSEcCtD
Pomalidomide—Hyperbilirubinaemia—Epirubicin—liver cancer	0.00068	0.00449	CcSEcCtD
Pomalidomide—Anaemia—Sorafenib—liver cancer	0.000676	0.00446	CcSEcCtD
Pomalidomide—Hypocalcaemia—Epirubicin—liver cancer	0.000676	0.00446	CcSEcCtD
Pomalidomide—Leukopenia—Sorafenib—liver cancer	0.000655	0.00432	CcSEcCtD
Pomalidomide—Bone pain—Epirubicin—liver cancer	0.000646	0.00426	CcSEcCtD
Pomalidomide—Cough—Sorafenib—liver cancer	0.000638	0.00421	CcSEcCtD
Pomalidomide—Hyperbilirubinaemia—Doxorubicin—liver cancer	0.000629	0.00415	CcSEcCtD
Pomalidomide—Musculoskeletal pain—Epirubicin—liver cancer	0.000626	0.00413	CcSEcCtD
Pomalidomide—Hypocalcaemia—Doxorubicin—liver cancer	0.000625	0.00412	CcSEcCtD
Pomalidomide—Arthralgia—Sorafenib—liver cancer	0.000623	0.00411	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.000619	0.00408	CcSEcCtD
Pomalidomide—Pulmonary embolism—Epirubicin—liver cancer	0.000619	0.00408	CcSEcCtD
Pomalidomide—Hyperkalaemia—Epirubicin—liver cancer	0.000608	0.00401	CcSEcCtD
Pomalidomide—Bone pain—Doxorubicin—liver cancer	0.000597	0.00394	CcSEcCtD
Pomalidomide—Infection—Sorafenib—liver cancer	0.000593	0.00391	CcSEcCtD
Pomalidomide—Nervous system disorder—Sorafenib—liver cancer	0.000586	0.00386	CcSEcCtD
Pomalidomide—Thrombocytopenia—Sorafenib—liver cancer	0.000585	0.00386	CcSEcCtD
Pomalidomide—Neuropathy—Epirubicin—liver cancer	0.000581	0.00383	CcSEcCtD
Pomalidomide—Skin disorder—Sorafenib—liver cancer	0.00058	0.00383	CcSEcCtD
Pomalidomide—Musculoskeletal pain—Doxorubicin—liver cancer	0.000579	0.00382	CcSEcCtD
Pomalidomide—Pulmonary embolism—Doxorubicin—liver cancer	0.000572	0.00378	CcSEcCtD
Pomalidomide—Hyperkalaemia—Doxorubicin—liver cancer	0.000562	0.00371	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Sorafenib—liver cancer	0.000544	0.00359	CcSEcCtD
Pomalidomide—Neuropathy—Doxorubicin—liver cancer	0.000537	0.00355	CcSEcCtD
Pomalidomide—Sepsis—Epirubicin—liver cancer	0.000537	0.00354	CcSEcCtD
Pomalidomide—Dyspnoea—Sorafenib—liver cancer	0.000532	0.00351	CcSEcCtD
Pomalidomide—Decreased appetite—Sorafenib—liver cancer	0.000519	0.00342	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Sorafenib—liver cancer	0.000516	0.0034	CcSEcCtD
Pomalidomide—Fatigue—Sorafenib—liver cancer	0.000515	0.0034	CcSEcCtD
Pomalidomide—Pain—Sorafenib—liver cancer	0.000511	0.00337	CcSEcCtD
Pomalidomide—Constipation—Sorafenib—liver cancer	0.000511	0.00337	CcSEcCtD
Pomalidomide—Sepsis—Doxorubicin—liver cancer	0.000497	0.00328	CcSEcCtD
Pomalidomide—Cardiac failure congestive—Epirubicin—liver cancer	0.000495	0.00327	CcSEcCtD
Pomalidomide—Body temperature increased—Sorafenib—liver cancer	0.000472	0.00311	CcSEcCtD
Pomalidomide—Cardiac failure congestive—Doxorubicin—liver cancer	0.000458	0.00302	CcSEcCtD
Pomalidomide—Hyponatraemia—Epirubicin—liver cancer	0.000451	0.00297	CcSEcCtD
Pomalidomide—Pain in extremity—Epirubicin—liver cancer	0.000449	0.00296	CcSEcCtD
Pomalidomide—Hypersensitivity—Sorafenib—liver cancer	0.00044	0.0029	CcSEcCtD
Pomalidomide—Asthenia—Sorafenib—liver cancer	0.000428	0.00283	CcSEcCtD
Pomalidomide—Pruritus—Sorafenib—liver cancer	0.000422	0.00279	CcSEcCtD
Pomalidomide—Blood creatinine increased—Epirubicin—liver cancer	0.000421	0.00278	CcSEcCtD
Pomalidomide—Dehydration—Epirubicin—liver cancer	0.000418	0.00275	CcSEcCtD
Pomalidomide—Hyponatraemia—Doxorubicin—liver cancer	0.000417	0.00275	CcSEcCtD
Pomalidomide—Pain in extremity—Doxorubicin—liver cancer	0.000415	0.00274	CcSEcCtD
Pomalidomide—Dry skin—Epirubicin—liver cancer	0.000412	0.00272	CcSEcCtD
Pomalidomide—Hypokalaemia—Epirubicin—liver cancer	0.000409	0.0027	CcSEcCtD
Pomalidomide—Diarrhoea—Sorafenib—liver cancer	0.000409	0.0027	CcSEcCtD
Pomalidomide—Breast disorder—Epirubicin—liver cancer	0.000406	0.00268	CcSEcCtD
Pomalidomide—Nasopharyngitis—Epirubicin—liver cancer	0.000401	0.00265	CcSEcCtD
Pomalidomide—Muscular weakness—Epirubicin—liver cancer	0.000396	0.00261	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Epirubicin—liver cancer	0.000396	0.00261	CcSEcCtD
Pomalidomide—Dizziness—Sorafenib—liver cancer	0.000395	0.00261	CcSEcCtD
Pomalidomide—Blood creatinine increased—Doxorubicin—liver cancer	0.000389	0.00257	CcSEcCtD
Pomalidomide—Dehydration—Doxorubicin—liver cancer	0.000386	0.00255	CcSEcCtD
Pomalidomide—Dry skin—Doxorubicin—liver cancer	0.000381	0.00251	CcSEcCtD
Pomalidomide—Vomiting—Sorafenib—liver cancer	0.00038	0.0025	CcSEcCtD
Pomalidomide—Hypokalaemia—Doxorubicin—liver cancer	0.000378	0.00249	CcSEcCtD
Pomalidomide—Rash—Sorafenib—liver cancer	0.000376	0.00248	CcSEcCtD
Pomalidomide—Dermatitis—Sorafenib—liver cancer	0.000376	0.00248	CcSEcCtD
Pomalidomide—Breast disorder—Doxorubicin—liver cancer	0.000375	0.00248	CcSEcCtD
Pomalidomide—Headache—Sorafenib—liver cancer	0.000374	0.00247	CcSEcCtD
Pomalidomide—Bronchitis—Epirubicin—liver cancer	0.000373	0.00246	CcSEcCtD
Pomalidomide—Nasopharyngitis—Doxorubicin—liver cancer	0.000371	0.00245	CcSEcCtD
Pomalidomide—Pancytopenia—Epirubicin—liver cancer	0.000369	0.00243	CcSEcCtD
Pomalidomide—Muscular weakness—Doxorubicin—liver cancer	0.000366	0.00242	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.000366	0.00242	CcSEcCtD
Pomalidomide—Neutropenia—Epirubicin—liver cancer	0.000363	0.00239	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Epirubicin—liver cancer	0.000361	0.00238	CcSEcCtD
Pomalidomide—Nausea—Sorafenib—liver cancer	0.000355	0.00234	CcSEcCtD
Pomalidomide—Weight increased—Epirubicin—liver cancer	0.000353	0.00233	CcSEcCtD
Pomalidomide—Weight decreased—Epirubicin—liver cancer	0.000351	0.00232	CcSEcCtD
Pomalidomide—Hyperglycaemia—Epirubicin—liver cancer	0.00035	0.00231	CcSEcCtD
Pomalidomide—Pneumonia—Epirubicin—liver cancer	0.000348	0.0023	CcSEcCtD
Pomalidomide—Infestation NOS—Epirubicin—liver cancer	0.000346	0.00228	CcSEcCtD
Pomalidomide—Infestation—Epirubicin—liver cancer	0.000346	0.00228	CcSEcCtD
Pomalidomide—Bronchitis—Doxorubicin—liver cancer	0.000345	0.00228	CcSEcCtD
Pomalidomide—Pancytopenia—Doxorubicin—liver cancer	0.000341	0.00225	CcSEcCtD
Pomalidomide—Renal failure—Epirubicin—liver cancer	0.00034	0.00224	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Epirubicin—liver cancer	0.000339	0.00224	CcSEcCtD
Pomalidomide—Urinary tract infection—Epirubicin—liver cancer	0.000336	0.00222	CcSEcCtD
Pomalidomide—Neutropenia—Doxorubicin—liver cancer	0.000336	0.00222	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Doxorubicin—liver cancer	0.000334	0.0022	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Epirubicin—liver cancer	0.000327	0.00216	CcSEcCtD
Pomalidomide—Weight increased—Doxorubicin—liver cancer	0.000327	0.00216	CcSEcCtD
Pomalidomide—Epistaxis—Epirubicin—liver cancer	0.000326	0.00215	CcSEcCtD
Pomalidomide—Weight decreased—Doxorubicin—liver cancer	0.000325	0.00214	CcSEcCtD
Pomalidomide—Hyperglycaemia—Doxorubicin—liver cancer	0.000324	0.00214	CcSEcCtD
Pomalidomide—Pneumonia—Doxorubicin—liver cancer	0.000322	0.00212	CcSEcCtD
Pomalidomide—Infestation—Doxorubicin—liver cancer	0.00032	0.00211	CcSEcCtD
Pomalidomide—Infestation NOS—Doxorubicin—liver cancer	0.00032	0.00211	CcSEcCtD
Pomalidomide—Renal failure—Doxorubicin—liver cancer	0.000315	0.00208	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Doxorubicin—liver cancer	0.000314	0.00207	CcSEcCtD
Pomalidomide—Urinary tract infection—Doxorubicin—liver cancer	0.000311	0.00205	CcSEcCtD
Pomalidomide—Urinary tract disorder—Epirubicin—liver cancer	0.000307	0.00202	CcSEcCtD
Pomalidomide—Oedema peripheral—Epirubicin—liver cancer	0.000306	0.00202	CcSEcCtD
Pomalidomide—Connective tissue disorder—Epirubicin—liver cancer	0.000305	0.00201	CcSEcCtD
Pomalidomide—Urethral disorder—Epirubicin—liver cancer	0.000304	0.00201	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Doxorubicin—liver cancer	0.000303	0.002	CcSEcCtD
Pomalidomide—Epistaxis—Doxorubicin—liver cancer	0.000302	0.00199	CcSEcCtD
Pomalidomide—Cardiac disorder—Epirubicin—liver cancer	0.000288	0.0019	CcSEcCtD
Pomalidomide—Urinary tract disorder—Doxorubicin—liver cancer	0.000284	0.00187	CcSEcCtD
Pomalidomide—Oedema peripheral—Doxorubicin—liver cancer	0.000283	0.00187	CcSEcCtD
Pomalidomide—Connective tissue disorder—Doxorubicin—liver cancer	0.000282	0.00186	CcSEcCtD
Pomalidomide—Angiopathy—Epirubicin—liver cancer	0.000282	0.00186	CcSEcCtD
Pomalidomide—Urethral disorder—Doxorubicin—liver cancer	0.000282	0.00186	CcSEcCtD
Pomalidomide—Mediastinal disorder—Epirubicin—liver cancer	0.00028	0.00185	CcSEcCtD
Pomalidomide—Chills—Epirubicin—liver cancer	0.000279	0.00184	CcSEcCtD
Pomalidomide—Mental disorder—Epirubicin—liver cancer	0.000272	0.0018	CcSEcCtD
Pomalidomide—Malnutrition—Epirubicin—liver cancer	0.00027	0.00178	CcSEcCtD
Pomalidomide—Cardiac disorder—Doxorubicin—liver cancer	0.000267	0.00176	CcSEcCtD
Pomalidomide—Back pain—Epirubicin—liver cancer	0.000262	0.00173	CcSEcCtD
Pomalidomide—Angiopathy—Doxorubicin—liver cancer	0.000261	0.00172	CcSEcCtD
Pomalidomide—Muscle spasms—Epirubicin—liver cancer	0.00026	0.00172	CcSEcCtD
Pomalidomide—Mediastinal disorder—Doxorubicin—liver cancer	0.000259	0.00171	CcSEcCtD
Pomalidomide—Chills—Doxorubicin—liver cancer	0.000258	0.0017	CcSEcCtD
Pomalidomide—Mental disorder—Doxorubicin—liver cancer	0.000252	0.00166	CcSEcCtD
Pomalidomide—Malnutrition—Doxorubicin—liver cancer	0.00025	0.00165	CcSEcCtD
Pomalidomide—Anaemia—Epirubicin—liver cancer	0.00025	0.00165	CcSEcCtD
Pomalidomide—Vertigo—Epirubicin—liver cancer	0.000243	0.0016	CcSEcCtD
Pomalidomide—Leukopenia—Epirubicin—liver cancer	0.000242	0.0016	CcSEcCtD
Pomalidomide—Back pain—Doxorubicin—liver cancer	0.000242	0.0016	CcSEcCtD
Pomalidomide—Muscle spasms—Doxorubicin—liver cancer	0.000241	0.00159	CcSEcCtD
Pomalidomide—Cough—Epirubicin—liver cancer	0.000236	0.00156	CcSEcCtD
Pomalidomide—Anaemia—Doxorubicin—liver cancer	0.000231	0.00153	CcSEcCtD
Pomalidomide—Arthralgia—Epirubicin—liver cancer	0.00023	0.00152	CcSEcCtD
Pomalidomide—Anxiety—Epirubicin—liver cancer	0.000229	0.00151	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000229	0.00151	CcSEcCtD
Pomalidomide—Vertigo—Doxorubicin—liver cancer	0.000225	0.00148	CcSEcCtD
Pomalidomide—Leukopenia—Doxorubicin—liver cancer	0.000224	0.00148	CcSEcCtD
Pomalidomide—Confusional state—Epirubicin—liver cancer	0.000223	0.00147	CcSEcCtD
Pomalidomide—Infection—Epirubicin—liver cancer	0.000219	0.00145	CcSEcCtD
Pomalidomide—Cough—Doxorubicin—liver cancer	0.000218	0.00144	CcSEcCtD
Pomalidomide—Nervous system disorder—Epirubicin—liver cancer	0.000216	0.00143	CcSEcCtD
Pomalidomide—Thrombocytopenia—Epirubicin—liver cancer	0.000216	0.00143	CcSEcCtD
Pomalidomide—Skin disorder—Epirubicin—liver cancer	0.000214	0.00141	CcSEcCtD
Pomalidomide—Hyperhidrosis—Epirubicin—liver cancer	0.000213	0.00141	CcSEcCtD
Pomalidomide—Arthralgia—Doxorubicin—liver cancer	0.000213	0.00141	CcSEcCtD
Pomalidomide—Anxiety—Doxorubicin—liver cancer	0.000212	0.0014	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000212	0.0014	CcSEcCtD
Pomalidomide—Confusional state—Doxorubicin—liver cancer	0.000206	0.00136	CcSEcCtD
Pomalidomide—Infection—Doxorubicin—liver cancer	0.000203	0.00134	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000201	0.00133	CcSEcCtD
Pomalidomide—Nervous system disorder—Doxorubicin—liver cancer	0.0002	0.00132	CcSEcCtD
Pomalidomide—Thrombocytopenia—Doxorubicin—liver cancer	0.0002	0.00132	CcSEcCtD
Pomalidomide—Insomnia—Epirubicin—liver cancer	0.0002	0.00132	CcSEcCtD
Pomalidomide—Skin disorder—Doxorubicin—liver cancer	0.000198	0.00131	CcSEcCtD
Pomalidomide—Hyperhidrosis—Doxorubicin—liver cancer	0.000197	0.0013	CcSEcCtD
Pomalidomide—Dyspnoea—Epirubicin—liver cancer	0.000197	0.0013	CcSEcCtD
Pomalidomide—Decreased appetite—Epirubicin—liver cancer	0.000192	0.00127	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Epirubicin—liver cancer	0.000191	0.00126	CcSEcCtD
Pomalidomide—Fatigue—Epirubicin—liver cancer	0.00019	0.00126	CcSEcCtD
Pomalidomide—Constipation—Epirubicin—liver cancer	0.000189	0.00125	CcSEcCtD
Pomalidomide—Pain—Epirubicin—liver cancer	0.000189	0.00125	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000186	0.00123	CcSEcCtD
Pomalidomide—Insomnia—Doxorubicin—liver cancer	0.000185	0.00122	CcSEcCtD
Pomalidomide—Dyspnoea—Doxorubicin—liver cancer	0.000182	0.0012	CcSEcCtD
Pomalidomide—Feeling abnormal—Epirubicin—liver cancer	0.000182	0.0012	CcSEcCtD
Pomalidomide—Decreased appetite—Doxorubicin—liver cancer	0.000177	0.00117	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000176	0.00116	CcSEcCtD
Pomalidomide—Fatigue—Doxorubicin—liver cancer	0.000176	0.00116	CcSEcCtD
Pomalidomide—Pain—Doxorubicin—liver cancer	0.000175	0.00115	CcSEcCtD
Pomalidomide—Constipation—Doxorubicin—liver cancer	0.000175	0.00115	CcSEcCtD
Pomalidomide—Body temperature increased—Epirubicin—liver cancer	0.000174	0.00115	CcSEcCtD
Pomalidomide—Feeling abnormal—Doxorubicin—liver cancer	0.000168	0.00111	CcSEcCtD
Pomalidomide—Hypersensitivity—Epirubicin—liver cancer	0.000163	0.00107	CcSEcCtD
Pomalidomide—Body temperature increased—Doxorubicin—liver cancer	0.000161	0.00106	CcSEcCtD
Pomalidomide—Asthenia—Epirubicin—liver cancer	0.000158	0.00104	CcSEcCtD
Pomalidomide—Pruritus—Epirubicin—liver cancer	0.000156	0.00103	CcSEcCtD
Pomalidomide—Diarrhoea—Epirubicin—liver cancer	0.000151	0.000996	CcSEcCtD
Pomalidomide—Hypersensitivity—Doxorubicin—liver cancer	0.00015	0.000993	CcSEcCtD
Pomalidomide—Asthenia—Doxorubicin—liver cancer	0.000146	0.000967	CcSEcCtD
Pomalidomide—Dizziness—Epirubicin—liver cancer	0.000146	0.000963	CcSEcCtD
Pomalidomide—Pruritus—Doxorubicin—liver cancer	0.000144	0.000953	CcSEcCtD
Pomalidomide—Vomiting—Epirubicin—liver cancer	0.00014	0.000926	CcSEcCtD
Pomalidomide—Diarrhoea—Doxorubicin—liver cancer	0.00014	0.000922	CcSEcCtD
Pomalidomide—Rash—Epirubicin—liver cancer	0.000139	0.000918	CcSEcCtD
Pomalidomide—Dermatitis—Epirubicin—liver cancer	0.000139	0.000917	CcSEcCtD
Pomalidomide—Headache—Epirubicin—liver cancer	0.000138	0.000912	CcSEcCtD
Pomalidomide—Dizziness—Doxorubicin—liver cancer	0.000135	0.000891	CcSEcCtD
Pomalidomide—Nausea—Epirubicin—liver cancer	0.000131	0.000865	CcSEcCtD
Pomalidomide—Vomiting—Doxorubicin—liver cancer	0.00013	0.000857	CcSEcCtD
Pomalidomide—Rash—Doxorubicin—liver cancer	0.000129	0.000849	CcSEcCtD
Pomalidomide—Dermatitis—Doxorubicin—liver cancer	0.000129	0.000849	CcSEcCtD
Pomalidomide—Headache—Doxorubicin—liver cancer	0.000128	0.000844	CcSEcCtD
Pomalidomide—Nausea—Doxorubicin—liver cancer	0.000121	0.0008	CcSEcCtD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK14—liver cancer	4.41e-05	0.000313	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—liver cancer	4.4e-05	0.000313	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	4.35e-05	0.000309	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TNF—liver cancer	4.34e-05	0.000309	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—LTF—liver cancer	4.33e-05	0.000308	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—liver cancer	4.32e-05	0.000307	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—TNF—liver cancer	4.24e-05	0.000301	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—UGDH—liver cancer	4.24e-05	0.000301	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	4.21e-05	0.000299	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—PPARG—liver cancer	4.21e-05	0.000299	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—AKT1—liver cancer	4.2e-05	0.000299	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—liver cancer	4.15e-05	0.000294	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—APC—liver cancer	4.09e-05	0.00029	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—liver cancer	4.06e-05	0.000289	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—GSTP1—liver cancer	4.01e-05	0.000285	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—EPT1—liver cancer	3.99e-05	0.000283	CbGpPWpGaD
Pomalidomide—CYP3A4—Metapathway biotransformation—GSTP1—liver cancer	3.96e-05	0.000281	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—liver cancer	3.95e-05	0.000281	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—liver cancer	3.95e-05	0.00028	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—AKT1—liver cancer	3.94e-05	0.00028	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—GGT1—liver cancer	3.93e-05	0.000279	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—liver cancer	3.92e-05	0.000278	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—MMP2—liver cancer	3.86e-05	0.000274	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TP53—liver cancer	3.83e-05	0.000272	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—liver cancer	3.83e-05	0.000272	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—TAT—liver cancer	3.78e-05	0.000269	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK8—liver cancer	3.73e-05	0.000265	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—GSTM1—liver cancer	3.69e-05	0.000262	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—AKT1—liver cancer	3.65e-05	0.000259	CbGpPWpGaD
Pomalidomide—CYP3A4—Metapathway biotransformation—GSTM1—liver cancer	3.64e-05	0.000258	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CPT1B—liver cancer	3.63e-05	0.000258	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GLUL—liver cancer	3.63e-05	0.000258	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	3.56e-05	0.000253	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—IL6—liver cancer	3.5e-05	0.000249	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—NR1H4—liver cancer	3.5e-05	0.000248	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—CYP1A1—liver cancer	3.5e-05	0.000248	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—liver cancer	3.45e-05	0.000245	CbGpPWpGaD
Pomalidomide—CYP3A4—Metapathway biotransformation—CYP1A1—liver cancer	3.45e-05	0.000245	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GSTA3—liver cancer	3.44e-05	0.000244	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—RAF1—liver cancer	3.42e-05	0.000243	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	3.4e-05	0.000241	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—UGDH—liver cancer	3.39e-05	0.000241	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—ALDOB—liver cancer	3.35e-05	0.000238	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—liver cancer	3.21e-05	0.000228	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—EPT1—liver cancer	3.18e-05	0.000226	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—liver cancer	3.17e-05	0.000225	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—liver cancer	3.16e-05	0.000225	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GSTA4—liver cancer	3.14e-05	0.000223	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	3.07e-05	0.000218	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GSTA2—liver cancer	3.06e-05	0.000218	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—TAT—liver cancer	3.02e-05	0.000214	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	2.97e-05	0.000211	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—CTNNB1—liver cancer	2.96e-05	0.00021	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GSTA1—liver cancer	2.96e-05	0.00021	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—liver cancer	2.95e-05	0.00021	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—liver cancer	2.94e-05	0.000209	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—liver cancer	2.93e-05	0.000208	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—NAT2—liver cancer	2.92e-05	0.000208	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—MMP9—liver cancer	2.9e-05	0.000206	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—liver cancer	2.88e-05	0.000205	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PPARA—liver cancer	2.81e-05	0.0002	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—liver cancer	2.8e-05	0.000199	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ALDOB—liver cancer	2.8e-05	0.000199	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—liver cancer	2.8e-05	0.000199	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—liver cancer	2.78e-05	0.000197	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—liver cancer	2.71e-05	0.000193	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—CYCS—liver cancer	2.7e-05	0.000192	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	2.69e-05	0.000191	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CRABP1—liver cancer	2.67e-05	0.00019	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—liver cancer	2.65e-05	0.000188	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—ADAM17—liver cancer	2.65e-05	0.000188	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—UGDH—liver cancer	2.61e-05	0.000186	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—VEGFA—liver cancer	2.61e-05	0.000185	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	2.6e-05	0.000185	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—STAT3—liver cancer	2.58e-05	0.000183	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CPT1B—liver cancer	2.57e-05	0.000183	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GLUL—liver cancer	2.57e-05	0.000183	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PSMD10—liver cancer	2.49e-05	0.000177	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PSMA4—liver cancer	2.49e-05	0.000177	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—NR1H4—liver cancer	2.48e-05	0.000176	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—EPT1—liver cancer	2.46e-05	0.000175	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—liver cancer	2.44e-05	0.000174	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GSTA3—liver cancer	2.44e-05	0.000173	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—GOT2—liver cancer	2.42e-05	0.000172	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	2.41e-05	0.000171	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—TGFB1—liver cancer	2.39e-05	0.00017	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—HMOX1—liver cancer	2.34e-05	0.000167	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—HPGDS—liver cancer	2.34e-05	0.000166	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—TAT—liver cancer	2.33e-05	0.000165	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PPARG—liver cancer	2.32e-05	0.000165	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—liver cancer	2.25e-05	0.00016	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—liver cancer	2.24e-05	0.000159	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GSTA4—liver cancer	2.23e-05	0.000158	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—GGT1—liver cancer	2.22e-05	0.000158	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—KRAS—liver cancer	2.22e-05	0.000157	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	2.2e-05	0.000156	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GSTA2—liver cancer	2.17e-05	0.000154	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	2.12e-05	0.00015	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GSTA1—liver cancer	2.1e-05	0.000149	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—liver cancer	2.09e-05	0.000149	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—ALB—liver cancer	2.09e-05	0.000148	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—GOT1—liver cancer	2.09e-05	0.000148	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PSMD10—liver cancer	2.08e-05	0.000148	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PSMA4—liver cancer	2.08e-05	0.000148	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—liver cancer	2.08e-05	0.000148	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—NAT2—liver cancer	2.07e-05	0.000147	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GLUL—liver cancer	2.05e-05	0.000146	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CPT1B—liver cancer	2.05e-05	0.000146	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GOT2—liver cancer	2.03e-05	0.000144	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ALDOB—liver cancer	1.99e-05	0.000141	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—NR1H4—liver cancer	1.98e-05	0.000141	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GSTA3—liver cancer	1.95e-05	0.000138	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PRKCE—liver cancer	1.93e-05	0.000137	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	1.91e-05	0.000136	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CYP2E1—liver cancer	1.9e-05	0.000135	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CRABP1—liver cancer	1.9e-05	0.000135	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—PPARA—liver cancer	1.89e-05	0.000135	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—HRAS—liver cancer	1.88e-05	0.000134	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	1.85e-05	0.000131	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	1.84e-05	0.000131	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—IL6—liver cancer	1.8e-05	0.000128	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CYCS—liver cancer	1.78e-05	0.000127	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GSTA4—liver cancer	1.78e-05	0.000126	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GGT1—liver cancer	1.75e-05	0.000124	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GOT1—liver cancer	1.75e-05	0.000124	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	1.74e-05	0.000124	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GSTA2—liver cancer	1.73e-05	0.000123	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—H2AFX—liver cancer	1.68e-05	0.000119	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GSTA1—liver cancer	1.67e-05	0.000119	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—AKT1—liver cancer	1.66e-05	0.000118	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—HPGDS—liver cancer	1.66e-05	0.000118	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—NAT2—liver cancer	1.65e-05	0.000117	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—liver cancer	1.59e-05	0.000113	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ALDOB—liver cancer	1.59e-05	0.000113	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GLUL—liver cancer	1.58e-05	0.000112	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CPT1B—liver cancer	1.58e-05	0.000112	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GSTP1—liver cancer	1.57e-05	0.000112	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	1.56e-05	0.000111	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—HMOX1—liver cancer	1.55e-05	0.00011	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—NR1H4—liver cancer	1.53e-05	0.000108	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MTHFR—liver cancer	1.52e-05	0.000108	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—TERT—liver cancer	1.52e-05	0.000108	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CRABP1—liver cancer	1.51e-05	0.000107	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GSTA3—liver cancer	1.5e-05	0.000107	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PSMD10—liver cancer	1.48e-05	0.000105	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PSMA4—liver cancer	1.48e-05	0.000105	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GSTM1—liver cancer	1.44e-05	0.000103	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GOT2—liver cancer	1.44e-05	0.000102	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—ALB—liver cancer	1.41e-05	0.0001	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GSTA4—liver cancer	1.37e-05	9.75e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CYP1A1—liver cancer	1.37e-05	9.72e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	1.36e-05	9.68e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CYP2E1—liver cancer	1.35e-05	9.59e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GSTA2—liver cancer	1.34e-05	9.51e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—HPGDS—liver cancer	1.32e-05	9.39e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—liver cancer	1.31e-05	9.34e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GSTA1—liver cancer	1.29e-05	9.17e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—APC—liver cancer	1.28e-05	9.09e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—NAT2—liver cancer	1.28e-05	9.07e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—MTHFR—liver cancer	1.28e-05	9.06e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—RAF1—liver cancer	1.27e-05	9.04e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CYCS—liver cancer	1.26e-05	8.97e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PPARA—liver cancer	1.25e-05	8.89e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GOT1—liver cancer	1.24e-05	8.81e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GGT1—liver cancer	1.24e-05	8.81e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ALDOB—liver cancer	1.22e-05	8.69e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—BRAF—liver cancer	1.2e-05	8.55e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	1.2e-05	8.51e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—liver cancer	1.18e-05	8.4e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PSMA4—liver cancer	1.18e-05	8.37e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PSMD10—liver cancer	1.18e-05	8.37e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CRABP1—liver cancer	1.17e-05	8.29e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GOT2—liver cancer	1.15e-05	8.14e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PIK3CD—liver cancer	1.13e-05	7.99e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.12e-05	7.99e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GSTP1—liver cancer	1.11e-05	7.91e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—SERPINE1—liver cancer	1.11e-05	7.91e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—HMOX1—liver cancer	1.1e-05	7.8e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CYP2E1—liver cancer	1.08e-05	7.66e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PIK3CG—liver cancer	1.07e-05	7.61e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	1.04e-05	7.41e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PPARG—liver cancer	1.03e-05	7.35e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GSTM1—liver cancer	1.02e-05	7.27e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—HPGDS—liver cancer	1.02e-05	7.25e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CYCS—liver cancer	1.01e-05	7.16e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—RAF1—liver cancer	1e-05	7.14e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GGT1—liver cancer	9.9e-06	7.03e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GOT1—liver cancer	9.9e-06	7.03e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MTOR—liver cancer	9.81e-06	6.97e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PIK3CB—liver cancer	9.81e-06	6.97e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CYP1A1—liver cancer	9.7e-06	6.89e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PIK3CD—liver cancer	9.42e-06	6.69e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ALB—liver cancer	9.3e-06	6.61e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CDKN1B—liver cancer	9.2e-06	6.54e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PSMD10—liver cancer	9.1e-06	6.46e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PSMA4—liver cancer	9.1e-06	6.46e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—MTHFR—liver cancer	9.04e-06	6.42e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GSTP1—liver cancer	8.89e-06	6.31e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PPARA—liver cancer	8.87e-06	6.3e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GOT2—liver cancer	8.85e-06	6.29e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—HMOX1—liver cancer	8.77e-06	6.23e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CTNNB1—liver cancer	8.7e-06	6.18e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CDKN1A—liver cancer	8.49e-06	6.03e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CYP2E1—liver cancer	8.32e-06	5.91e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PIK3CB—liver cancer	8.21e-06	5.83e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GSTM1—liver cancer	8.17e-06	5.8e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CYCS—liver cancer	7.78e-06	5.53e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CYP1A1—liver cancer	7.74e-06	5.5e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GGT1—liver cancer	7.64e-06	5.43e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GOT1—liver cancer	7.64e-06	5.43e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PIK3CG—liver cancer	7.6e-06	5.4e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—STAT3—liver cancer	7.58e-06	5.38e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PPARG—liver cancer	7.33e-06	5.21e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—MTHFR—liver cancer	7.22e-06	5.13e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PPARA—liver cancer	7.08e-06	5.03e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MYC—liver cancer	7.04e-06	5e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—TGFB1—liver cancer	7.03e-06	4.99e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GSTP1—liver cancer	6.86e-06	4.87e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—HMOX1—liver cancer	6.77e-06	4.81e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PIK3CD—liver cancer	6.68e-06	4.75e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ALB—liver cancer	6.59e-06	4.68e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—KRAS—liver cancer	6.51e-06	4.62e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	6.36e-06	4.52e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GSTM1—liver cancer	6.31e-06	4.48e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PIK3CG—liver cancer	6.07e-06	4.31e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PIK3CA—liver cancer	5.98e-06	4.25e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CYP1A1—liver cancer	5.98e-06	4.25e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PPARG—liver cancer	5.85e-06	4.16e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PIK3CB—liver cancer	5.82e-06	4.14e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—MTHFR—liver cancer	5.57e-06	3.96e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HRAS—liver cancer	5.53e-06	3.93e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PPARA—liver cancer	5.47e-06	3.88e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PIK3CD—liver cancer	5.33e-06	3.79e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—IL6—liver cancer	5.29e-06	3.76e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ALB—liver cancer	5.26e-06	3.74e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PIK3CA—liver cancer	5.01e-06	3.56e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—AKT1—liver cancer	4.88e-06	3.47e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PIK3CG—liver cancer	4.68e-06	3.33e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PIK3CB—liver cancer	4.65e-06	3.3e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PPARG—liver cancer	4.52e-06	3.21e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PIK3CD—liver cancer	4.12e-06	2.92e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—AKT1—liver cancer	4.09e-06	2.91e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ALB—liver cancer	4.06e-06	2.89e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PIK3CB—liver cancer	3.59e-06	2.55e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PIK3CA—liver cancer	3.55e-06	2.52e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—AKT1—liver cancer	2.9e-06	2.06e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PIK3CA—liver cancer	2.83e-06	2.01e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—AKT1—liver cancer	2.31e-06	1.64e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PIK3CA—liver cancer	2.19e-06	1.55e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—AKT1—liver cancer	1.79e-06	1.27e-05	CbGpPWpGaD
